These preliminary data showed encouraging results in terms of safety and tolerability at 12 months in ALS patients; however, and more interestingly, data from autoptic studies in a subgroup of patients suggested graft survival and satisfactory GDNF production. The gene discussed is GDNF; the disease is amyotrophic lateral sclerosis.